

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

NCI-H1573

RRID:CVCL_1478

Type: Cell Line

Proper Citation

RRID:CVCL_1478

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1478

Proper Citation: RRID:CVCL_1478

Description: Cell line NCI-H1573 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:8806092](#), [PMID:11030152](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H1573

Synonyms: H1573, H-1573, NCIH1573

Cross References: CLO:CLO_0008002, EFO:EFO_0002256, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5877, BioSample:SAMN03472584, BioSample:SAMN10987661, cancercellines:CVCL_1478, Cell_Model_Passport:SIDM00749, ChEMBL-Cells:ChEMBL3308117, ChEMBL-Targets:ChEMBL1075515, Cosmic:687796, Cosmic:877243, Cosmic:877425,

Cosmic:903595, Cosmic:908472, Cosmic:1995526, Cosmic:2125179, Cosmic-CLP:908472, DepMap:ACH-000916, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:908472, GEO:GSM794321, GEO:GSM827530, GEO:GSM887368, GEO:GSM888446, GEO:GSM1670177, IARC_TP53:496, IGRhCellID:NCIH1573, KCLB:91573, LiGeA:CCLE_321, LINCS_LDP:LCL-1638, PharmacDB:NCIH1573_1023_2019, PRIDE:PXD030304, Progenetix:CVCL_1478, PubChem_Cell_line:CVCL_1478, Wikidata:Q54907825

ID: CVCL_1478

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260920T004612+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H1573.

No alerts have been found for NCI-H1573.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. Molecular cancer research : MCR, 24(1), 60.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer cell, 43(3), 464.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer cell, 43(8), 1530.

Suvilesh KN, et al. (2024) Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(17), 3855.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. International journal of cancer, 154(6), 1029.

Fukuda K, et al. (2024) Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. Cell reports. Medicine, 5(6),

101578.

Köferle A, et al. (2022) Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes. *Cell reports*, 39(2), 110636.

Kwon M, et al. (2022) Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis. *Cancer research communications*, 2(10), 1197.

Yang J, et al. (2021) An IFN γ /STAT1/JMJD3 Axis Induces ZEB1 Expression and Promotes Aggressiveness in Lung Adenocarcinoma. *Molecular cancer research : MCR*, 19(7), 1234.

Gonzalez Rajal A, et al. (2021) A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinoma. *eLife*, 10.

Guerra SL, et al. (2020) A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. *Cancer cell*, 37(5), 705.

LeBoeuf SE, et al. (2020) Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids. *Cell metabolism*, 31(2), 339.

Hastings JF, et al. (2020) Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. *eLife*, 9.

Gymnopoulos M, et al. (2020) TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. *Molecular oncology*, 14(1), 54.

Yin N, et al. (2019) Protein Kinase C δ and Wnt/ β -Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma. *Cancer cell*, 36(2), 156.